(Q34792836)

4 August 2017

1 reference

title

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs (English)

1 reference

4 August 2017

Doriano Fabbro

1

1 reference

4 August 2017

Stephan Ruetz

2

1 reference

4 August 2017

Elisabeth Buchdunger

3

1 reference

4 August 2017

Sandra W Cowan-Jacob

4

1 reference

4 August 2017

Gabriele Fendrich

5

1 reference

4 August 2017

Janis Liebetanz

6

1 reference

4 August 2017

Jürgen Mestan

7

1 reference

4 August 2017

Terence O'Reilly

8

1 reference

4 August 2017

Peter Traxler

9

1 reference

4 August 2017

Bhabatosh Chaudhuri

10

1 reference

4 August 2017

Heinz Fretz

11

1 reference

4 August 2017

Jürg Zimmermann

12

1 reference

4 August 2017

Thomas Meyer

13

1 reference

4 August 2017

Giorgio Caravatti

14

1 reference

4 August 2017

Pascal Furet

15

1 reference

4 August 2017

Paul W Manley

16

1 reference

4 August 2017

1 February 2002

1 reference

Pharmacology & Therapeutics

4 August 2017

1 reference

4 August 2017

93

1 reference

4 August 2017

2-3

1 reference

4 August 2017

79-98

1 reference

Mice without telomerase: what can they teach us about human cancer?

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Molecular targets for breast cancer therapy and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

How receptors talk to trimeric G proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

UICC study group on basic and clinical cancer research: Animal models for the natural history of cancer. Meeting held at Woods Hole, MA (USA), June 21-23, 1999. International Union Against Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Chronic myelogenous leukemia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Specificity and mechanism of action of some commonly used protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Crystal structure of cyclin-dependent kinase 2

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

The pathway to signal achievement

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Structural aspects of protein kinase control-role of conformational flexibility

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Structure-based design of potent CDK1 inhibitors derived from olomoucine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

1 reference

7 January 2021

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Rb function in cell-cycle regulation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cyclin-Dependent Kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cell cycle control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Crystal structure of the tyrosine kinase domain of the human insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Signaling--2000 and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Characterization of novel inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Targeting signal transduction for disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cyclin-dependent kinase inhibitors: novel anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

1 reference

7 January 2021

Tumor angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Multiple signals converging on NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Mouse models for sporadic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Lysophosphatidic acid: G-protein signalling and cellular responses

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Mitotic kinases as regulators of cell division and its checkpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

In vivo imaging of light-emitting probes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Inhibition of CDKs as a therapeutic modality.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cell signaling by receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Small molecule modulators of cyclin-dependent kinases for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Preclinical and clinical development of cyclin-dependent kinase modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

1 reference

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Novel Cdk inhibitors restore TGF-beta sensitivity in cdk4 overexpressing epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cyclin-dependent kinase inhibitors for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Tyrosine kinase inhibitors: from rational design to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cycling, stressed-out and nervous: cellular functions of c-Abl

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Cell-cycle checkpoint kinases: checking in on the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

DNA damage: Chk1 and Cdc25, more than meets the eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Regulation of cell death by the Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Signaling pathways activated by oncogenic forms of Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

Imaging metalloproteinase activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2802%2900179-1

7 January 2021

10.1016/S0163-7258(02)00179-1

Identifiers

DOI

1 reference

4 August 2017

1 reference